» Articles » PMID: 15780590

Phosphoinositide 3-kinase in Disease: Timing, Location, and Scaffolding

Overview
Publisher Elsevier
Specialty Cell Biology
Date 2005 Mar 23
PMID 15780590
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

When PI3Ks are deregulated by aberrant surface receptors or modulators, accumulation of PtdIns(3,4,5)P3 leads to increased cell growth, proliferation and contact-independent survival. The PI3K/PKB/TOR axis controls protein synthesis and growth, while PtdIns(3,4,5)P3-mediated activation of Rho GTPases directs cell motility. PI3K activity has been linked to the formation of tumors, metastasis, chronic inflammation, allergy and cardiovascular disease. Although increased PtdIns(3,4,5)P3 is a well-established cause of disease, it is seldom known which PI3K isoform is implied. Recent work has demonstrated that PI3Kgamma contributes to the control of cAMP levels in the cardiac system, where the protein acts as a scaffold, but not as a lipid kinase.

Citing Articles

Formyl-peptide receptor 2 signalling triggers aerobic metabolism of glucose through Nox2-dependent modulation of pyruvate dehydrogenase activity.

Cimmino T, Pagano E, Stornaiuolo M, Esposito G, Ammendola R, Cattaneo F Open Biol. 2023; 13(10):230336.

PMID: 37875162 PMC: 10597678. DOI: 10.1098/rsob.230336.


PI3Kβ-regulated β-catenin mediates EZH2 removal from promoters controlling primed human ESC stemness and primitive streak gene expression.

Yadav S, Garrido A, Hernandez M, Oliveros J, Perez-Garcia V, Fraga M Stem Cell Reports. 2022; 17(10):2239-2255.

PMID: 36179694 PMC: 9561645. DOI: 10.1016/j.stemcr.2022.09.003.


The role of PI3Kγ in the immune system: new insights and translational implications.

Lanahan S, Wymann M, Lucas C Nat Rev Immunol. 2022; 22(11):687-700.

PMID: 35322259 PMC: 9922156. DOI: 10.1038/s41577-022-00701-8.


Chemical and Structural Strategies to Selectively Target mTOR Kinase.

Borsari C, De Pascale M, Wymann M ChemMedChem. 2021; 16(18):2744-2759.

PMID: 34114360 PMC: 8518124. DOI: 10.1002/cmdc.202100332.


Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.

Borsari C, Keles E, Treyer A, De Pascale M, Hebeisen P, Hamburger M RSC Med Chem. 2021; 12(4):579-583.

PMID: 34041490 PMC: 8128076. DOI: 10.1039/d0md00408a.